查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1862519

近距离放射治疗市场：按剂量率、最终用户、产品、治疗类型和应用划分 - 全球预测（2025-2032 年）

Brachytherapy Market by Dose Rate, End User, Product, Treatment Type, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，近距离放射治疗市场规模将达到 16.1 亿美元，复合年增长率为 5.99%。

关键市场统计数据
基准年 2024 10.1亿美元
预计年份：2025年 10.7亿美元
预测年份 2032 16.1亿美元
复合年增长率 (%) 5.99%

近距离放射、技术进步以及影响其当前应用和实践的战略考虑。

近距离放射已成为现代肿瘤治疗的重要组成部分。其核心在于能够以高生物疗效将适形放射治疗精准地输送到特定标靶区，同时保护邻近正常组织。随着影像、治疗计划和实施技术的日益成熟，近距离放射技术已从传统的低剂量率植入发展到多种高精度方法，并整合了三维成像和影像引导的自适应工作流程。本文概述了影响临床医生、管理人员和技术开发人员对近距离放射说明的临床因素、技术驱动因素以及相关人员的优先事项。

临床上，对于某些疾病部位而言，局部控制和器官保留能够显着提高患者的生活质量，因此这种治疗方法仍然至关重要。技术进步（例如，改进的自动化后荷机、先进的施用器设计和新型放射源选择）以及先进的影像技术，缩短了手术时间，提高了治疗的可重复性，并扩大了适合间质和腔内治疗的患者群体。同时，手术场所也更加多样化，包括专业的门诊机构、综合癌症中心和传统医院手术室，改变了治疗路径和资金规划需求。

从策略角度来看，相关人员必须权衡临床结果与手术流程效率、资本密集度、培训需求和监管路径。在整合放射肿瘤学、医学物理和外科专业的跨学科团队中，手术流程是创造价值的核心。本导言概述了当前的临床原理、正在重塑实践的技术基础以及影响采购和实施决策的经济和营运因素，为深入分析奠定了基础。

治疗平台、影像整合和临床实践的融合发展如何从根本上重塑近距离放射治疗的治疗模式和技术应用

由于设备工程、影像整合和临床证据完善等方面的整合进步，近距离放射领域正经历着变革性的转变。首先，输送平台的演进强调精准性和操控性。远端后装自动化、改进的针头和施用器几何形状以及数位化连接功能正在减少人为操作的差异，并提高手术的可重复性。因此，医疗团队能够实施更一致的剂量绘製策略并缩短术中工作流程，进而影响治疗路径和资源分配。

其次，先进影像技术在治疗过程中的应用正在重塑标靶区定义和检验的方式。能够实现即时或近实时可视化的成像方式有助于建立更严格的安全边界和自适应治疗计划，使临床医生能够在控制毒性的同时，对抗药性肿瘤亚区进行剂量强化。同时，小型化感测器和改进的传输装置正在加强放射源管理系统和施用器系统之间的联繫，减少治疗过程中的摩擦，并提高品质保证流程中的数据可追溯性。

第三，随着证据不断明确疾病部位与跨技术适应症，临床实务模式日益完善。成熟的间质和腔内疗法正与混合疗法和标靶表面治疗相结合，从而形成更丰富的治疗套件。医疗机构的应对措施也在转变，效率的提高、更明确的患者选择标准以及当日出院通讯协定使得某些手术能够在门诊手术中心进行。这些变革性的变化迫使医疗设备製造商、服务供应商和临床领导者重新思考其产品开发、培训和实施策略，以适应以精准性、高效率和以患者为中心的显着疗效为优先的医疗保健生态系统。

评估2025年关税变化及其对近距离放射治疗供应链、筹资策略、临床营运和政策参与的实际影响

2025年的政策环境引入了关税调整，这将对近距离放射治疗行业的供应链、筹资策略和营运预算产生重大影响。影响医疗设备和放射性材料物流的关税变化进一步凸显了建立稳健的采购系统和加强监管合规计画的重要性。对于依赖复杂跨境供应链的机构而言，额外的成本和海关相关的不确定性迫使它们重新评估采购计划，并与製造商和经销商密切合作，以避免治疗计划中断。

在营运层面，关税促使企业采取多项策略性应变措施。医疗服务提供者和经销商增加了库存缓衝，并修订了合约条款，纳入了前置作业时间紧急应变和价格保护条款。製造商正在加快本地化生产，并调整供应链网络，以降低关税波动带来的风险。这些调整往往需要权衡利弊，虽然在已实施的地区提高了可预测性，但也给资本配置和营运利润率带来了压力。

临床上，这些上游影响促使人们更加重视耗材使用的标准化和手术流程效率的最佳化。多学科团队正在审查医疗设备使用通讯协定，并探索在保持临床疗效的同时，减少对单一来源组件依赖的方案。从监管和政策角度来看，这些关税调整凸显了行业相关人员和政策制定者之间持续合作的必要性，以确保医疗服务的连续性，并在满足国内产业目标的同时，兼顾提供高品质、及时肿瘤治疗的实际情况。

透过详细的細項分析，将剂量率、最终用户、产品配置、治疗类型和临床应用与策略性产品选择和实施决策联繫起来。

理解细分市场的细微差别对于解读整个近距离放射治疗流程中的应用模式、产品优先排序以及临床工作流程的影响至关重要。从剂量率的角度来看，高剂量率 (HDR)、低剂量率 (LDR) 和脉衝剂量率 (PDR) 模式之间的差异对临床适应症、手术物流和资源规划具有重要意义。高剂量率系统强调借助先进的后荷机和精确的放射源管理实现短时高强度治疗。同时，低剂量率方法仍然是某些适应症的持久解决方案，在这些适应症中，延长治疗时间具有临床优势。脉衝剂量率方法则介于两者之间，兼顾了生物学因素和实际工作流程的特征。

最终使用者的特征会显着影响需求模式和采购行为。例如，门诊手术中心优先考虑的是能够简化人员配置并加快患者周转的紧凑高效系统，而癌症研究所则重视多学科工作流程、研究能力以及与复杂规划基础设施的整合。医院通常兼顾这两种需求，需要能够部署于住院和门诊环境并与其整体资本设备策略一致的多功能解决方案。

产品细分决定了设计要求和服务模式。后荷机分为手动和遥控两种，需要在安全性、自动化和使用者人体工学之间取得平衡。手动系统在资源有限的环境或特定操作流程中仍然适用，而遥控系统则支援自动化方案整合并降低医护人员的辐射暴露。施放器及其配件（包括施放器、针头和运输装置）的设计必须以优化定位精度、病患舒适度和灭菌流程为目标。放射源的选择，包括铯-137、碘-125、铱-192、钯-103和钇-90等放射性核种，决定了屏蔽措施、法规遵循和临床剂量策略。

治疗方法（间质治疗、腔内治疗和表浅治疗）的差异决定了手术的复杂性和器械的兼容性。间质治疗需要可调节的针头系统和精确的容积规划，腔内治疗依赖于施放器的几何形状和稳定性，而浅表治疗则依赖适用于不同解剖部位的可调节施放器和固定机制。此外，乳房、妇科、头颈部和前列腺等特定应用领域对产品和工作流程提出了不同的要求。乳房治疗包括混合疗法、MamSite 和 SAVIScout 等技术，每种技术在植入技术和患者选择方面各有优劣。妇科治疗则根据肿瘤扩散程度结合间质治疗、腔内治疗和表浅治疗。同时，头颈部治疗又细分为更具体的区域——喉部、口腔和口咽部——需要在入路、剂量和功能保留之间取得平衡。前列腺治疗策略根据植入方式的不同而有所差异，包括永久性植入和植入植入技术，以及在放射源处理、影像追踪和患者咨询等方面的操作差异。这些细分维度指南产品蓝图、培训重点和商业化策略，使相关人员能够针对不同的临床情况优化最佳方案。

区域对比分析重点阐述了美洲、欧洲、中东和非洲以及亚太地区的趋势将如何影响临床应用、报销和部署策略。

区域趋势将对近距离近距离放射技术的应用时机、监管路径和商业模式产生决定性影响。美洲地区拥有多元化的医疗服务体系，涵盖公立和私人医疗机构，部分地区聚集了许多学术机构，这些机构推动临床创新和手术流程的改善。报销机制和机构资本週期影响采购时间表，尤其註重透过结合手术和放射治疗的综合治疗路径来优化治疗效果。

欧洲、中东和非洲地区（EMEA）的管理体制和医疗基础设施错综复杂。在欧洲部分地区，统一的监管标准和集中化的报销流程加速了实证技术的应用。同时，中东和北非（MENA）各市场的基础设施成熟度差异显着，这为模组化、成本效益高的解决方案和能力建设倡议创造了机会。在全部区域，人才培育、跨国合作以及官民合作关係是指导技术应用策略的常见方向。

亚太地区肿瘤服务的快速现代化、对三级医疗机构的大量投资以及日益重视精准医疗以符合人口健康优先事项的特点，都是其显着特征。该地区的规模和多样性推动了实用、扩充性解决方案的采用，从而能够在都市区进行大规模部署并覆盖更广泛的地域。供应链韧性、与当地监管机构的合作以及与区域临床领导者的伙伴关係是成功进入市场和持续推广的通用要素。在所有地区，使产品价值提案与当地的医保报销体系、医疗服务提供者的能力和医疗服务模式相匹配，对于产生有意义的临床和商业性影响至关重要。

竞争格局概述显示，整合平台、专业创新者和以服务主导的模式正在重塑供应商选择和长期伙伴关係关係。

近距离放射治疗领域的竞争动态反映了现有产品系列与专注于特定临床需求和工作流程优化的敏捷创新者之间的平衡。领先的医疗设备製造商正投资于整合系统，这些系统整合了后荷机、施放施用器系统、治疗计画软体和服务框架，旨在提供全面的解决方案，以解决医疗服务提供者对互通性和生命週期支援的担忧。这些公司通常强调循证实践、法规遵从性以及广泛的培训计划，以支持在各种临床环境中推广应用。

同时，专业供应商和新兴Start-Ups正积极寻求差异化策略，针对特定手术步骤，例如新型施药器设计、改进的输送装置或先进的放射源技术，以缩短手术时间并改善剂量学结果。医疗设备製造商与卓越临床中心之间的合作正在加速产品检验并改善使用者体验，从而降低机构核准和临床医生接受的门槛。服务模式也在不断发展，包括供应管理协议、耗材订阅框架和远端规划协助，这反映了客户对可预测营运成本和专业知识的需求。

对于采购人员和临床领导者而言，供应商的选择越来越侧重于整体拥有成本、培训和支援、监管记录以及特定手术获益的证据。那些能够展现可靠的上市后监测、健全的品管体係以及积极主动的监管沟通的供应商，更有可能赢得长期的机构合约。在这种竞争激烈的环境中，与最终用户共同开发解决方案的合作关係，透过将产品功能与日常临床实践相结合，能够创造可持续的竞争优势。

领导者在增强互通性、模组化产品设计、供应链韧性以及产生可操作的证据以促进持续采用方面，面临着切实可行的策略挑战。

行业领导者应优先考虑切实可行的策略，以使临床结果与永续的商业模式相契合。首先，应投资于互通性操作系统和开放资料标准，以促进后荷机、规划软体、影像设备和医院资讯系统之间的整合。这将有助于减少实施过程中的阻力，并支持利用即时数据进行品质保证和结果评估的自适应诊疗路径。

接下来，我们将开发模组化产品系列，可根据不同终端用户的需求进行客製化，从面向门诊手术中心的简化解决方案到面向癌症研究机构的综合平台，从而实现更精准的市场细分。与模组化设计同步，我们将拓展培训和认证项目，以提升临床医生的熟练程度，降低手术操作的差异性，从而支持可预测的患者治疗效果。

第三，我们将透过多元化零件采购、建立区域分销中心以及协商灵活的合约条款（充分考虑关税和物流方面的不确定性）来增强供应链韧性。在采取供应链措施的同时，我们将推进积极主动的监管应对计划，并儘早与相关人员就卫生技术评估进行沟通，以明确区域报销框架内的价值提案。

最后，我们将推进循证实践倡议技术创新与可衡量的临床和经济终点联繫起来。务实的多中心註册研究和有针对性的真实世界研究无需进行长期随机试验即可展现比较优势，从而提供支付方和医疗机构采购方日益需要的数据。透过结合技术互通性、模组化设计、营运弹性以及以证据为导向的策略，行业领导者可以加速负责任地推广应用，并为患者和医疗保健系统带来持续价值。

透过透明的三角调查方法，结合关键相关利益者访谈、技术文献回顾和供应链分析，获得严谨的洞见。

本分析的调查方法采用三角测量法，结合与关键相关利益者的对话、技术文献的综合分析以及供应链检验，以确保可靠的实务证据基础。主要资料来源包括与临床医生、医学物理学家、采购人员和医疗设备工程师的结构化访谈，以深入了解实际操作流程、实施限制和未满足的临床需求。此外，还对同行评审的临床文献、医疗设备技术文件和监管指南进行了深入审查，以检验临床性能声明并阐明安全考虑。

透过供应链图谱绘製和供应商访谈，我们确定了製造地、分销模式和常见的物流瓶颈，从而获取营运情报。政策和报销评估参考了公共指导文件和支付方框架说明，以了解不同医疗保健系统如何评估产品价值。在整个过程中，我们与领域专家进行了多次迭代整合会议，交叉检验了我们的发现，以协调不同的观点并检验观察到的模式。

我们的分析方法采用定性主题编码来识别反覆出现的挑战和机会，并建立了设备能力比较矩阵来突出差异化功能。我们的调查方法强调资讯来源的透明度、分析过程的可重复性，以及与临床顾问的持续回馈机制，以确保结论是基于实际操作。对于已发表证据有不足之处的情况，我们注记相关专家的意见，以阐明潜在的实践模式，并明确指出其基本假设的性质。

本文探讨如何将临床效用、技术复杂性和运行弹性结合，以最大限度地发挥近距离放射在现代肿瘤学中的潜力。

总之，近距离放射治疗仍然是一项临床上至关重要的治疗方法，它受益于技术的不断改进、工作流程的最佳化以及针对性证据的累积。此治疗方法的优点在于能够提供局部、高精度的治疗，显着提高器官保留率和患者生活质量，尤其是在整合到局部诊疗路径中时。随着治疗系统的自动化程度不断提高以及影像融合技术的发展，治疗流程的效率和可重复性将进一步提升，使其能够应用于更广泛的临床场景。

然而，相关人员必须应对不断变化的采购趋势、监管要求以及影响医疗资源取得和营运永续性的供应链因素。针对每家机构（无论是门诊手术中心、癌症研究所还是医院）的独特需求量身定制产品，设计模组化和可互操作系统，并优先考虑可操作的证据生成，这些都是将技术可能性与临床和组织实际情况相结合的关键步骤。最终，该领域的成功将取决于能否将工程创新转化为持续的临床效益和精简的医疗服务，同时维持一个具有韧性和合规性的供应链生态系统。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 基于先进影像技术的前列腺癌个人化低剂量率近距离放射治疗粒子植入术
  • 引入一种高剂量率远端装载系统，该系统整合即时剂量测定功能，用于子宫颈癌治疗
  • 开发可生物降解的间隔物以减少周围正常组织受到的辐射暴露
  • 整合人工智慧驱动的治疗计划软体以优化近距离放射治疗中的种子放置和剂量分布
  • 利用球囊导管系统扩大腔内近距离放射治疗在早期乳癌的应用
  • 推出用于复杂妇科及头颈部近距离放射治疗手术的3D列印客製化施用器

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依剂量率分類的近距离放射治疗市场

  • 高剂量率
  • 低剂量率
  • 脉衝剂量率

第九章 依最终使用者分類的近距离放射治疗市场

  • 门诊手术中心
  • 癌症研究所
  • 医院

第十章 近距离放射治疗产品市场

  • 后荷机
    • 手动输入
    • 遥控类型
  • 涂抹器和配件
    • 应用程式
    • 针
    • 转移装置
  • 放射性物质
    • Cs-137
    • I-125
    • Ir-192
    • Pd-103
    • Y-90

第十一章 近距离放射治疗市场（依治疗方法划分）

  • 间质疗法
  • 腔内照射
  • 表面辐射

第十二章 按应用分類的近距离放射治疗市场

  • 胸部
    • 杂交种
    • 猛犸象遗址
    • SAVIScout
  • 妇科
    • 间质疗法
    • 腔内照射
    • 表面辐射
  • 头部和颈部
    • 喉
    • 口腔
    • 口咽
  • 摄护腺
    • 永久植入式
    • 暂时植入

第十三章 区域近距离放射治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 按组别分類的近距离放射治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国近距离放射治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Varian Medical Systems, Inc.
    • Elekta AB（publ）
    • CR Bard, Inc.
    • Eckert & Ziegler AG
    • Ion Beam Applications SA
    • Best Medical International, Inc.
    • IsoRay, Inc.
    • Theragenics Corporation
    • Beijing Atom High Tech Co., Ltd.
    • NTP Radioisotopes SOC Limited
Product Code: MRR-521BAA36EB3B

The Brachytherapy Market is projected to grow by USD 1.61 billion at a CAGR of 5.99% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.01 billion
Estimated Year [2025] USD 1.07 billion
Forecast Year [2032] USD 1.61 billion
CAGR (%) 5.99%

A succinct yet comprehensive overview of brachytherapy's clinical importance, technological advances, and strategic considerations shaping adoption and delivery today

Brachytherapy occupies a pivotal niche in contemporary oncologic care, anchored by its capacity to deliver conformal radiation with high biological effectiveness to defined targets while sparing adjacent normal tissues. As imaging, treatment planning, and delivery technologies have matured, brachytherapy techniques have expanded from classic low dose rate implants to a diverse suite of high precision approaches that integrate three-dimensional imaging and image-guided adaptive workflows. This introduction synthesizes clinical drivers, technological enablers, and stakeholder priorities that together shape how brachytherapy is evaluated by clinicians, administrators, and technology developers.

Clinically, the modality remains indispensable for specific disease sites where local control and organ preservation yield meaningful quality-of-life advantages. Technological progress such as improved afterloader automation, advanced applicator design, and novel source options have converged with enhanced imaging modalities to reduce procedure times, increase reproducibility, and broaden the patient cohorts amenable to interstitial and intracavitary approaches. In parallel, procedural settings have diversified to include specialized ambulatory environments, integrated oncology centers, and traditional hospital theaters, altering care pathways and capital planning prescriptions.

From a strategic perspective, stakeholders must weigh clinical performance against procedural throughput, capital intensity, training requirements, and regulatory pathways. As multidisciplinary teams integrate radiation oncology, medical physics, and surgical specialties, the procedural workflow becomes a central locus for value creation. This introduction establishes the baseline context for deeper analysis by outlining the contemporary clinical rationale, the technical building blocks redefining practice, and the economic and operational considerations that inform procurement and adoption decisions.

How convergent advances in delivery platforms, imaging integration, and clinical practice are fundamentally reshaping brachytherapy care delivery and technology adoption

The brachytherapy landscape is experiencing transformative shifts driven by convergent advances in device engineering, imaging integration, and clinical evidence refinement. First, the evolution of delivery platforms has emphasized precision and usability; remote afterloading automation, refined needle and applicator geometries, and digital connectivity features are reducing manual variability and enhancing procedural reproducibility. As a result, teams are able to implement more consistent dose painting strategies and shortened intraoperative workflows, which in turn influences care pathways and resource allocation.

Second, the integration of advanced imaging into the treatment chain is reshaping how targets are defined and verified. Modalities that enable real-time or near-real-time visualization support tighter margins and adaptive replanning, thereby allowing clinicians to escalate dose to resistant tumor subvolumes while controlling toxicity. Concurrently, miniaturized sensors and improved transfer devices are enhancing the interface between source management and applicator systems, reducing procedural friction and improving data traceability for quality assurance processes.

Third, clinical practice patterns are becoming more nuanced as evidence clarifies indications across disease sites and techniques. Hybrid approaches and targeted surface treatments are emerging alongside established interstitial and intracavitary therapies, creating a richer procedural toolkit. Institutional pathways are also adapting, with ambulatory surgical centers increasingly able to host select procedures due to improvements in efficiency, patient selection, and same-day discharge protocols. These transformative shifts collectively mandate that device makers, service providers, and clinical leaders rethink product development, training, and deployment strategies to align with a healthcare ecosystem that prizes precision, throughput, and demonstrable patient-centered outcomes.

Assessment of 2025 tariff shifts and their practical implications for brachytherapy supply chains, procurement strategies, clinical operations, and policy engagement

The policy environment in 2025 introduced tariff adjustments that have material implications for supply chains, procurement strategies, and operating budgets across the brachytherapy sector. Tariff changes affecting medical devices and radioactive source logistics have accentuated the importance of resilient sourcing and enhanced regulatory-compliance planning. Organizations that rely on complex cross-border supply chains have found that incremental costs and customs-related uncertainties require revised procurement timelines and closer coordination with manufacturers and distributors to avoid disruption to treatment schedules.

Operationally, the tariffs have prompted several strategic responses. Healthcare providers and distributors have expanded inventory buffering and revisited contractual terms to incorporate lead-time contingencies and price-protection clauses. Manufacturers have accelerated efforts to localize production or adapt supply networks to mitigate exposure to tariff volatility. These adaptations often carry their own trade-offs, creating pressure on capital allocation and operational margins while improving predictability where implemented.

Clinically, the upstream effects translate into an increased emphasis on standardizing consumable use and optimizing procedural efficiency. Multidisciplinary teams are reassessing device utilization protocols and exploring options that maintain clinical outcomes while reducing dependency on single-source components. From a regulatory and policy vantage, these tariff dynamics underscore the need for sustained engagement between industry stakeholders and policymakers to ensure continuity of care and to balance domestic industrial objectives with the practical realities of delivering high-quality, timely oncology services.

Deep segmentation analysis linking dose rate, end user, product architecture, treatment type, and clinical application to strategic product and deployment decisions

A nuanced understanding of segmentation is essential to interpret adoption patterns, product priorities, and clinical workflow implications across the brachytherapy continuum. When viewed through the lens of dose rate, distinctions among High Dose Rate, Low Dose Rate, and Pulse Dose Rate modalities inform clinical indications, procedural logistics, and resource planning. High Dose Rate systems emphasize brief, high-intensity treatments enabled by advanced afterloaders and precise source control, while Low Dose Rate approaches continue to provide durable solutions for specific indications where prolonged exposure profiles are clinically advantageous. Pulse Dose Rate occupies an intermediary role, balancing biological considerations with practical workflow features.

End-user differentiation significantly affects demand characteristics and procurement behavior. Ambulatory Surgical Centers prioritize compact, efficient systems with streamlined staffing and rapid turnover, whereas Cancer Institutes emphasize integration with multidisciplinary workflows, research capabilities, and complex planning infrastructures. Hospitals often straddle both priorities, requiring versatile solutions that can be deployed across inpatient and outpatient settings and that align with broader capital equipment strategies.

Product segmentation drives design imperatives and service models. Afterloaders, divided into manual and remote variants, must balance safety, automation, and user ergonomics; manual systems retain relevance for low-resource contexts and specific procedural preferences, while remote systems support automated planning integration and reduced radiation exposure for staff. Applicator and accessory portfolios-spanning applicators, needles, and transfer devices-require designs that optimize placement accuracy, patient comfort, and sterilization workflows. Source selection, encompassing radionuclides such as Cs-137, I-125, Ir-192, Pd-103, and Y-90, shapes shielding, regulatory handling, and clinical dosing strategies.

Treatment type differentiation among Interstitial, Intracavitary, and Surface approaches dictates procedural complexity and device compatibility. Interstitial treatments demand adaptable needle systems and precise volumetric planning, intracavitary techniques hinge on applicator geometry and stability, and surface modalities rely on conformal applicators and attachment mechanisms suitable for varying anatomical sites. Finally, application-specific considerations across Breast, Gynecological, Head And Neck, and Prostate domains impose distinct product and workflow requirements. Breast applications include technologies such as Hybrid approaches, MammoSite, and SAVIScout, each offering different trade-offs in implantation technique and patient selection. Gynecological practice incorporates interstitial, intracavitary, and surface options to address a spectrum of tumor extents, while head and neck interventions are subdivided into laryngeal, oral, and oropharyngeal niches that demand careful balancing of access, dosimetry, and functional preservation. Prostate strategies differentiate permanent implant techniques from temporary implant approaches, with divergent logistics around source handling, imaging follow-up, and patient counseling. Together, these segmentation axes inform product roadmaps, training priorities, and commercialization tactics as stakeholders optimize offerings for distinct clinical contexts.

Comparative regional intelligence highlighting how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics shape clinical adoption, reimbursement, and deployment strategies

Regional dynamics exert a decisive influence on technology adoption timelines, regulatory pathways, and commercial models for brachytherapy. In the Americas, healthcare delivery systems exhibit heterogeneity across private and public providers, with strong pockets of academic centers that drive clinical innovation and procedural refinement. Reimbursement frameworks and institutional capital cycles shape procurement timetables, and there is a notable emphasis on integrated care pathways that combine surgical and radiation modalities to optimize outcomes.

The Europe, Middle East & Africa region presents a complex mosaic of regulatory regimes and healthcare infrastructures. In parts of Europe, harmonized regulatory standards and centralized reimbursement processes can accelerate the diffusion of evidence-backed technologies, while markets in the Middle East and Africa offer divergent levels of infrastructure maturity that create opportunities for modular, cost-conscious solutions and capacity-building initiatives. Across the region, emphasis on workforce training, cross-border collaborations, and public-private partnerships frequently guides implementation strategies.

Asia-Pacific is characterized by rapid modernization of oncology services, substantial investments in tertiary care facilities, and a growing emphasis on precision therapies that align with population health priorities. The region's scale and heterogeneity encourage both large-scale deployments in urban centers and adoption of pragmatic, scalable solutions for broader geographic coverage. Supply chain resilience, local regulatory engagement, and partnerships with regional clinical leaders are common themes that inform successful market entry and sustained adoption. Across all regions, contextualizing product value propositions to local reimbursement, workforce capabilities, and care delivery models remains essential for meaningful clinical and commercial impact.

Competitive landscape overview showing how integrated platforms, focused innovators, and service-driven models are reshaping supplier selection and long-term partnerships

Competitive dynamics in brachytherapy reflect a balance between established players with broad product portfolios and nimble innovators focusing on niche clinical needs or workflow optimization. Leading device manufacturers invest in integrated systems that combine afterloaders, applicator ecosystems, treatment planning software, and service frameworks to present comprehensive solutions that address institutional concerns about interoperability and lifecycle support. These players typically emphasize evidence generation, regulatory compliance, and extensive training programs to support adoption across diverse care settings.

Simultaneously, specialized vendors and start-up entrants pursue differentiated strategies by targeting specific procedural steps, such as novel applicator designs, improved transfer devices, or advanced source technologies that can reduce procedural time or improve dosimetric outcomes. Partnerships between device manufactures and clinical centers of excellence accelerate product validation and refine user experience, thereby lowering barriers to institutional approval and clinician acceptance. Service models have also evolved to include managed supply agreements, consumable subscription frameworks, and remote planning support, reflecting customer preferences for predictable operating costs and access to specialized expertise.

For purchasers and clinical leaders, supplier selection increasingly weighs total cost of ownership, training and support capabilities, regulatory track record, and evidence of procedure-specific benefits. Vendors that demonstrate reliable post-market surveillance, robust quality management systems, and proactive regulatory engagement are better positioned to win long-term institutional commitments. In this competitive context, collaborative engagements that co-develop solutions with end users create durable advantages by aligning product feature sets with day-to-day clinical realities.

Practical strategic imperatives for leaders to enhance interoperability, modular product design, supply resilience, and pragmatic evidence generation for sustained adoption

Industry leaders should prioritize a set of actionable strategies to align clinical outcomes with sustainable commercial models. First, invest in interoperable systems and open data standards that facilitate integration between afterloaders, planning software, imaging modalities, and hospital information systems. This will reduce implementation friction and support adaptive care pathways that leverage real-time data for quality assurance and outcome measurement.

Second, develop modular product portfolios that can be tailored to different end-user needs-from streamlined solutions for ambulatory surgical centers to comprehensive platforms for cancer institutes-thereby enabling more precise go-to-market segmentation. Alongside modularity, expand training and credentialing programs to accelerate clinician proficiency and to reduce variability in procedural performance, which in turn supports predictable patient outcomes.

Third, strengthen supply chain resilience by diversifying component sourcing, establishing regional distribution hubs, and negotiating flexible contractual terms that account for tariff and logistics uncertainties. Complement supply-chain actions with proactive regulatory planning and early engagement with health technology assessment stakeholders to clarify value propositions within local reimbursement frameworks.

Finally, pursue evidence-generation initiatives that link procedural innovations to measurable clinical and economic endpoints. Pragmatic, multi-center registries and targeted real-world studies can demonstrate comparative advantages without requiring lengthy randomized trials, and they provide the data that payers and institutional buyers increasingly demand. By combining technical interoperability, modular design, operational resilience, and focused evidence strategies, industry leaders can accelerate responsible adoption and deliver sustained value for patients and health systems.

Transparent, triangulated research methodology combining primary stakeholder interviews, technical literature synthesis, and supply chain analysis for rigorous insights

The research methodology underpinning this analysis draws upon a triangulated approach that combines primary stakeholder engagement, technical literature synthesis, and supply chain examination to ensure a robust and actionable evidence base. Primary inputs include structured interviews with clinicians, medical physicists, procurement leaders, and device engineers to capture real-world insights on procedural workflows, deployment constraints, and unmet clinical needs. These conversations are complemented by an in-depth review of peer-reviewed clinical literature, device technical documentation, and regulatory guidance to validate clinical performance claims and to contextualize safety considerations.

Operational intelligence was obtained through supply chain mapping and vendor interviews, which identified manufacturing footprints, distribution models, and common logistics bottlenecks. Policy and reimbursement assessments incorporated public guidance documents and payer framework descriptions to understand how product value is appraised across different healthcare systems. Throughout the process, findings were cross-validated through iterative synthesis sessions with domain experts to reconcile divergent perspectives and to test the plausibility of observed patterns.

Analytical techniques included qualitative thematic coding to identify recurrent challenges and opportunities, as well as comparative device feature matrices to highlight differentiating capabilities. The methodology emphasizes transparency in source attribution, reproducibility of analytical steps, and a continuous feedback loop with clinical advisors to ensure that conclusions remain grounded in operational realities. Where gaps in public evidence existed, targeted expert elicitation was used to clarify probable practice patterns while explicitly noting the nature of the underlying assumptions.

Concluding synthesis on how clinical utility, technological refinement, and operational resilience must align to realize brachytherapy's full potential in modern oncology

In conclusion, brachytherapy continues to be a clinically vital modality benefiting from sustained technological refinement, workflow optimization, and targeted evidence development. The modality's strength lies in its capacity to deliver localized, high-precision therapy with meaningful implications for organ preservation and patient quality of life, particularly when integrated into multidisciplinary care pathways. As delivery systems become more automated and imaging integration advances, the modality's procedural efficiency and reproducibility are likely to improve, making it accessible to a broader range of clinical settings.

Stakeholders must, however, navigate evolving procurement dynamics, regulatory requirements, and supply chain considerations that shape access and operational sustainability. Tailoring product offerings to the distinct needs of ambulatory surgical centers, cancer institutes, and hospitals; designing modular, interoperable systems; and prioritizing pragmatic evidence generation will be essential steps to align technological potential with clinical and institutional realities. Ultimately, success in this space will be measured by the ability to translate engineering innovations into consistent clinical benefit and streamlined care delivery while maintaining a resilient and compliant supply ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Personalized low-dose-rate brachytherapy seed implants for prostate cancer guided by advanced imaging techniques
  • 5.2. Adoption of high-dose-rate remote afterloading systems with integrated real-time dosimetry for cervical cancer treatment
  • 5.3. Development of biodegradable brachytherapy spacers to minimize radiation exposure to surrounding healthy tissues
  • 5.4. Integration of AI-driven treatment planning software to optimize seed placement and dose distribution in brachytherapy
  • 5.5. Expansion of intracavitary brachytherapy applications for early-stage breast cancer using balloon catheter systems
  • 5.6. Emergence of 3D-printed customized applicators for complex gynecological and head and neck brachytherapy procedures

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brachytherapy Market, by Dose Rate

  • 8.1. High Dose Rate
  • 8.2. Low Dose Rate
  • 8.3. Pulse Dose Rate

9. Brachytherapy Market, by End User

  • 9.1. Ambulatory Surgical Centers
  • 9.2. Cancer Institutes
  • 9.3. Hospitals

10. Brachytherapy Market, by Product

  • 10.1. Afterloaders
    • 10.1.1. Manual
    • 10.1.2. Remote
  • 10.2. Applicator And Accessory
    • 10.2.1. Applicators
    • 10.2.2. Needles
    • 10.2.3. Transfer Devices
  • 10.3. Sources
    • 10.3.1. Cs-137
    • 10.3.2. I-125
    • 10.3.3. Ir-192
    • 10.3.4. Pd-103
    • 10.3.5. Y-90

11. Brachytherapy Market, by Treatment Type

  • 11.1. Interstitial
  • 11.2. Intracavitary
  • 11.3. Surface

12. Brachytherapy Market, by Application

  • 12.1. Breast
    • 12.1.1. Hybrid
    • 12.1.2. MammoSite
    • 12.1.3. SAVIScout
  • 12.2. Gynecological
    • 12.2.1. Interstitial
    • 12.2.2. Intracavitary
    • 12.2.3. Surface
  • 12.3. Head And Neck
    • 12.3.1. Laryngeal
    • 12.3.2. Oral
    • 12.3.3. Oropharyngeal
  • 12.4. Prostate
    • 12.4.1. Permanent Implant
    • 12.4.2. Temporary Implant

13. Brachytherapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brachytherapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brachytherapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Varian Medical Systems, Inc.
    • 16.3.2. Elekta AB (publ)
    • 16.3.3. C.R. Bard, Inc.
    • 16.3.4. Eckert & Ziegler AG
    • 16.3.5. Ion Beam Applications S.A.
    • 16.3.6. Best Medical International, Inc.
    • 16.3.7. IsoRay, Inc.
    • 16.3.8. Theragenics Corporation
    • 16.3.9. Beijing Atom High Tech Co., Ltd.
    • 16.3.10. NTP Radioisotopes SOC Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRACHYTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRACHYTHERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRACHYTHERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BRACHYTHERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRACHYTHERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BRACHYTHERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRACHYTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRACHYTHERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRACHYTHERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HIGH DOSE RATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HIGH DOSE RATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HIGH DOSE RATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HIGH DOSE RATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HIGH DOSE RATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HIGH DOSE RATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LOW DOSE RATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LOW DOSE RATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LOW DOSE RATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LOW DOSE RATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LOW DOSE RATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LOW DOSE RATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PULSE DOSE RATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PULSE DOSE RATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PULSE DOSE RATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PULSE DOSE RATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PULSE DOSE RATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PULSE DOSE RATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRACHYTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRACHYTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MANUAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MANUAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MANUAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MANUAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MANUAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REMOTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REMOTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REMOTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REMOTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REMOTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REMOTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRACHYTHERAPY MARKET SIZE, BY NEEDLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRACHYTHERAPY MARKET SIZE, BY NEEDLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRACHYTHERAPY MARKET SIZE, BY NEEDLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRACHYTHERAPY MARKET SIZE, BY NEEDLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRACHYTHERAPY MARKET SIZE, BY NEEDLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRACHYTHERAPY MARKET SIZE, BY NEEDLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TRANSFER DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TRANSFER DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TRANSFER DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TRANSFER DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TRANSFER DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TRANSFER DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SOURCES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SOURCES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SOURCES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SOURCES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SOURCES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SOURCES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CS-137, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CS-137, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CS-137, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CS-137, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CS-137, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CS-137, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRACHYTHERAPY MARKET SIZE, BY I-125, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRACHYTHERAPY MARKET SIZE, BY I-125, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRACHYTHERAPY MARKET SIZE, BY I-125, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRACHYTHERAPY MARKET SIZE, BY I-125, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRACHYTHERAPY MARKET SIZE, BY I-125, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRACHYTHERAPY MARKET SIZE, BY I-125, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRACHYTHERAPY MARKET SIZE, BY IR-192, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRACHYTHERAPY MARKET SIZE, BY IR-192, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRACHYTHERAPY MARKET SIZE, BY IR-192, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRACHYTHERAPY MARKET SIZE, BY IR-192, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRACHYTHERAPY MARKET SIZE, BY IR-192, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRACHYTHERAPY MARKET SIZE, BY IR-192, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PD-103, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PD-103, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PD-103, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PD-103, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PD-103, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PD-103, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRACHYTHERAPY MARKET SIZE, BY Y-90, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRACHYTHERAPY MARKET SIZE, BY Y-90, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRACHYTHERAPY MARKET SIZE, BY Y-90, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRACHYTHERAPY MARKET SIZE, BY Y-90, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRACHYTHERAPY MARKET SIZE, BY Y-90, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRACHYTHERAPY MARKET SIZE, BY Y-90, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRACHYTHERAPY MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRACHYTHERAPY MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRACHYTHERAPY MARKET SIZE, BY BREAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRACHYTHERAPY MARKET SIZE, BY BREAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRACHYTHERAPY MARKET SIZE, BY BREAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRACHYTHERAPY MARKET SIZE, BY BREAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRACHYTHERAPY MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRACHYTHERAPY MARKET SIZE, BY BREAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HYBRID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HYBRID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HYBRID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HYBRID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HYBRID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HYBRID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MAMMOSITE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MAMMOSITE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MAMMOSITE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MAMMOSITE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MAMMOSITE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MAMMOSITE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SAVISCOUT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SAVISCOUT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SAVISCOUT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SAVISCOUT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SAVISCOUT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SAVISCOUT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LARYNGEAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LARYNGEAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LARYNGEAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LARYNGEAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LARYNGEAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LARYNGEAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BRACHYTHERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BRACHYTHERAPY MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BRACHYTHERAPY MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BRACHYTHERAPY MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BRACHYTHERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BRACHYTHERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BRACHYTHERAPY MARKET SIZE, BY OROPHARYNGEAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BRACHYTHERAPY MARKET SIZE, BY OROPHARYNGEAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BRACHYTHERAPY MARKET SIZE, BY OROPHARYNGEAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BRACHYTHERAPY MARKET SIZE, BY OROPHARYNGEAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BRACHYTHERAPY MARKET SIZE, BY OROPHARYNGEAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BRACHYTHERAPY MARKET SIZE, BY OROPHARYNGEAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PROSTATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PROSTATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PROSTATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PROSTATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PERMANENT IMPLANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PERMANENT IMPLANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PERMANENT IMPLANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PERMANENT IMPLANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PERMANENT IMPLANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PERMANENT IMPLANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TEMPORARY IMPLANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TEMPORARY IMPLANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TEMPORARY IMPLANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TEMPORARY IMPLANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TEMPORARY IMPLANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TEMPORARY IMPLANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS BRACHYTHERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS BRACHYTHERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS BRACHYTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS BRACHYTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS BRACHYTHERAPY MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS BRACHYTHERAPY MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS BRACHYTHERAPY MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS BRACHYTHERAPY MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 330. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2018-2024 (USD MILLION)
  • TABLE 342. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2025-2032 (USD MILLION)
  • TABLE 343. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2018-2024 (USD MILLION)
  • TABLE 344. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2025-2032 (USD MILLION)
  • TABLE 345. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 348. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 349. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 350. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION